LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="le Comte, Marianne"
  2. AU="Datta, Karuna"
  3. AU="Kang, Zhuo"
  4. AU="Bloomquist, Jeffrey R"
  5. AU="Madas, Sapna"
  6. AU="Pickerodt, P. A."
  7. AU="Samtleben, D F E"
  8. AU="Cantile, Monica"
  9. AU="Acosta Gómez, Anyela"
  10. AU="Sarah Keefe"
  11. AU="Rossman, Jeremy S"
  12. AU="Zhou, Jiajun"
  13. AU="Arnoldini, Markus"
  14. AU="Pratt, Andy C."
  15. AU="Silva, Jéssica Coutinho"
  16. AU=Li Qing
  17. AU="Anita Matić"
  18. AU="Mazzocchi, Giampiero"

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: What the Product Label Does Not Tell You About Drug-Drug Interaction Management: Time for a Re-Appraisal.

    Burger, David M / le Comte, Marianne / Smolders, Elise J / Jacobs, Tom G / Ter Heine, Rob / Knibbe, Catherijne A J / Pirmohamed, Munir

    Journal of clinical pharmacology

    2023  Band 63, Heft 11, Seite(n) 1181–1185

    Sprache Englisch
    Erscheinungsdatum 2023-08-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188980-1
    ISSN 1552-4604 ; 0091-2700 ; 0021-9754
    ISSN (online) 1552-4604
    ISSN 0091-2700 ; 0021-9754
    DOI 10.1002/jcph.2316
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uf I Zs.176: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management.

    van Leeuwen, Roelof W F / le Comte, Marianne / Reyners, Anna K L / van den Tweel, Annemieke / van Vlijmen, Bas / Kwee, Wilma / Wensveen, Brigit / Steeghs, Neeltje / Visser, Otto / van Gelder, Teun / Jansman, Frank G A

    Seminars in oncology

    2022  Band 49, Heft 2, Seite(n) 119–129

    Abstract: Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch Multidisciplinary Expert group is assessing the clinical significance of DDIs in oncology and provides ... ...

    Abstract Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch Multidisciplinary Expert group is assessing the clinical significance of DDIs in oncology and provides recommendations for the management of these DDIs. We present an overview of methodology and outcome of an evidence- and consensus-based assessment of DDIs between anticancer drugs and non-anticancer drugs. A literature search was performed through PubMed and EMA and FDA assessment reports, to identify potential DDI's involving anticancer drugs. For each potential DDI a concept report for risk analysis and practical advice for management was created. Subsequently, this risk analysis and the corresponding advice were assessed and weighed. A total of 290 potential DDIs have been identified in the literature thus far. Of these 290 potential DDIs, the Expert Group has identified 94 (32%) DDIs as clinically relevant, with a need for an automated alert and a suggested intervention. Furthermore, 110 DDIs have been identified as clinically not relevant. For 86 potential DDIs evidence supporting a relevant DDI was insufficient and in these cases neither an alert nor advice regarding a suggested intervention were formulated. A transparent risk analysis is presented for identification of clinically relevant DDIs with anticancer drugs. Integration of DDI guidelines into the national electronic prescribing system is essential to achieve optimal efficacy and minimal toxicity in patients receiving anticancer therapy. A clear overview of clinically relevant DDIs with anticancer therapy provides clinicians with a structured, evidence-based and consensus-built tool for anticancer therapy surveillance.
    Mesh-Begriff(e) Antineoplastic Agents/adverse effects ; Consensus ; Drug Interactions ; Humans
    Chemische Substanzen Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2022-03-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    DOI 10.1053/j.seminoncol.2022.03.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1348: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Recommendations for selecting drug-drug interactions for clinical decision support.

    Tilson, Hugh / Hines, Lisa E / McEvoy, Gerald / Weinstein, David M / Hansten, Philip D / Matuszewski, Karl / le Comte, Marianne / Higby-Baker, Stefanie / Hanlon, Joseph T / Pezzullo, Lynn / Vieson, Kathleen / Helwig, Amy L / Huang, Shiew-Mei / Perre, Anthony / Bates, David W / Poikonen, John / Wittie, Michael A / Grizzle, Amy J / Brown, Mary /
    Malone, Daniel C

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

    2016  Band 73, Heft 8, Seite(n) 576–585

    Abstract: Purpose: Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented.: Summary: A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug ... ...

    Abstract Purpose: Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented.
    Summary: A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug information, and CDS from academia, government agencies, health information vendors, and healthcare organizations was convened to address (1) the process to use for developing and maintaining a standard set of DDIs, (2) the information that should be included in a knowledge base of standard DDIs, (3) whether a list of contraindicated drug pairs can or should be established, and (4) how to more intelligently filter DDI alerts. We recommend a transparent, systematic, and evidence-driven process with graded recommendations by a consensus panel of experts and oversight by a national organization. We outline key DDI information needed to help guide clinician decision-making. We recommend judicious classification of DDIs as contraindicated and more research to identify methods to safely reduce repetitive and less-relevant alerts.
    Conclusion: An expert panel with a centralized organizer or convener should be established to develop and maintain a standard set of DDIs for CDS in the United States. The process should be evidence driven, transparent, and systematic, with feedback from multiple stakeholders for continuous improvement. The scope of the expert panel's work should be carefully managed to ensure that the process is sustainable. Support for research to improve DDI alerting in the future is also needed. Adoption of these steps may lead to consistent and clinically relevant content for interruptive DDIs, thus reducing alert fatigue and improving patient safety.
    Mesh-Begriff(e) Alert Fatigue, Health Personnel/prevention & control ; Clinical Decision-Making ; Consensus ; Decision Support Systems, Clinical/standards ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Medical Order Entry Systems/standards ; United States
    Sprache Englisch
    Erscheinungsdatum 2016-03-14
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1224627-x
    ISSN 1535-2900 ; 1079-2082
    ISSN (online) 1535-2900
    ISSN 1079-2082
    DOI 10.2146/ajhp150565
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 419: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Interactie tussen clopidogrel en protonpompremmers.

    Harmsze, Ankie M / de Boer, Anthonius / Boot, Henk / Deneer, Vera H M / Heringa, Mette / Mol, Peter G M / Schalekamp, Tom / Verduijn, Monique M / Verheugt, Freek W A / le Comte, Marianne

    Nederlands tijdschrift voor geneeskunde

    2011  Band 155, Heft 28, Seite(n) A2442

    Abstract: The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel- ... ...

    Titelübersetzung Interaction between clopidogrel and proton pump inhibitors.
    Abstract The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.
    Mesh-Begriff(e) Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Cytochrome P-450 Enzyme System/metabolism ; Drug Interactions ; Drug Therapy, Combination ; Esomeprazole ; Gastrointestinal Hemorrhage/chemically induced ; Humans ; Omeprazole/adverse effects ; Omeprazole/metabolism ; Omeprazole/pharmacokinetics ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/metabolism ; Platelet Aggregation Inhibitors/pharmacokinetics ; Proton Pump Inhibitors/adverse effects ; Proton Pump Inhibitors/metabolism ; Proton Pump Inhibitors/pharmacokinetics ; Ticlopidine/adverse effects ; Ticlopidine/analogs & derivatives ; Ticlopidine/metabolism ; Ticlopidine/pharmacokinetics
    Chemische Substanzen Platelet Aggregation Inhibitors ; Proton Pump Inhibitors ; Cytochrome P-450 Enzyme System (9035-51-2) ; clopidogrel (A74586SNO7) ; Omeprazole (KG60484QX9) ; Esomeprazole (N3PA6559FT) ; Ticlopidine (OM90ZUW7M1)
    Sprache Niederländisch
    Erscheinungsdatum 2011
    Erscheinungsland Netherlands
    Dokumenttyp English Abstract ; Journal Article ; Review
    ZDB-ID 82073-8
    ISSN 1876-8784 ; 0028-2162
    ISSN (online) 1876-8784
    ISSN 0028-2162
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.18: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Consensus-based evaluation of clinical significance and management of anticancer drug interactions.

    Jansman, Frank G A / Reyners, An K L / van Roon, Eric N / Smorenburg, Carolien H / Helgason, Helgi H / le Comte, Marianne / Wensveen, Brigit M / van den Tweel, Annemieke M A / de Blois, Mieke / Kwee, Wilma / Kerremans, Adrian L / Brouwers, Jacobus R B J

    Clinical therapeutics

    2011  Band 33, Heft 3, Seite(n) 305–314

    Abstract: Background: Anticancer drug interactions can affect the efficacy and toxicity of anticancer treatment and that of the interacting drugs. However, information on the significance, prevention, and management of these interactions is currently lacking.: ... ...

    Abstract Background: Anticancer drug interactions can affect the efficacy and toxicity of anticancer treatment and that of the interacting drugs. However, information on the significance, prevention, and management of these interactions is currently lacking.
    Objective: The purpose of this study was to assess the clinical significance of interaction among anticancer agents and comedications and to provide recommendations for the management of clinically significant interactions.
    Methods: Members of a multidisciplinary expert group of hospital and community pharmacists, medical oncologists, internists, and clinical pharmacologists were selected by their professional organizations, which participated in this consensus project. Literature was extensively searched for any drug interactions with anticancer agents using registration files, reference books, handbooks, and electronic databases. Interactions between anticancer agents were not considered. Interactions were classified by level of best available evidence for the interaction and by severity of the clinical effect, according to a structured assessment procedure. This assessment distinguished 5 levels for the amount and quality of evidence available and 6 severity levels for classification of potential drug-to-drug interactions.
    Results: A total of 88 drug interactions with anticancer agents were identified from 146 combinations of drugs with anticancer agents found in literature. For 58 combinations, there was insufficient evidence of an interaction. Of the identified interactions, 38 were classified as clinically significant, defined as necessitating an alert or intervention, such as dose adaptation, comedication, discontinuation of treatment, or additional monitoring of treatment. Recommendations were made for management of these interactions.
    Conclusion: Numerous interactions with anticancer agents are clinically significant and should be considered by pharmacists and doctors in daily oncology practice.
    Mesh-Begriff(e) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Consensus ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/therapy ; Expert Testimony ; Humans ; Netherlands
    Chemische Substanzen Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2011-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 603113-4
    ISSN 1879-114X ; 0149-2918
    ISSN (online) 1879-114X
    ISSN 0149-2918
    DOI 10.1016/j.clinthera.2011.01.022
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1435: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 404: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: Clinical relevance of drug-drug interactions : a structured assessment procedure.

    van Roon, Eric N / Flikweert, Sander / le Comte, Marianne / Langendijk, Pim N J / Kwee-Zuiderwijk, Wilma J M / Smits, Paul / Brouwers, Jacobus R B J

    Drug safety

    2005  Band 28, Heft 12, Seite(n) 1131–1139

    Abstract: Introduction: Computerised drug interaction surveillance systems (CIS) may be helpful in detecting clinically significant drug interactions. Experience with CIS reveals that they often yield alerts with questionable clinical significance, fail to ... ...

    Abstract Introduction: Computerised drug interaction surveillance systems (CIS) may be helpful in detecting clinically significant drug interactions. Experience with CIS reveals that they often yield alerts with questionable clinical significance, fail to provide relevant information on risk factors for the adverse reaction of the interaction and fail to detect all significant drug interactions. These problems highlight the importance of transparency and selectivity in choosing the drug interactions to be included in CIS. In The Netherlands, the Working Group on Pharmacotherapy and Drug Information is responsible for maintenance of the CIS of the Royal Dutch Association for the Advancement of Pharmacy (KNMP).
    Methods: The Working Group developed an evidence-based procedure for structured assessment of drug-drug interactions and revised all drug interactions in the CIS accordingly.
    Results: For every drug interaction four core parameters were assessed: (i) evidence on the interaction; (ii) clinical relevance of the potential adverse reaction resulting from the interaction; (iii) risk factors identifying patient, medication or disease characteristics for which the interaction is of special importance; and (iv) the incidence of the adverse reaction. On the basis of this assessment the drug-drug interactions for inclusion in the CIS were selected. After revision of the drug combinations in the KNMP-CIS, the Working Group judged 22% of the combinations to be not interacting and another 12% to be interacting but not requiring action. On the basis of this assessment the subset of drug combinations for which interaction alerts are generated and the information on management of a drug interaction alert for users of the CIS were adapted. When an alert is generated by the CIS, the user of the system is supplied with comprehensive information on the four core parameters, the mechanism of the interaction and critical information for management of the interaction for the individual patient.
    Discussion: This structured procedure offers the possibility for transparent and reproducible assessment of the clinical relevance of drug interactions.
    Conclusion: A CIS selectively generating interaction alerts based on this assessment may help in realising the goal of good clinical practice and may offer a methodology to further increase drug safety.
    Mesh-Begriff(e) Adverse Drug Reaction Reporting Systems ; Clinical Pharmacy Information Systems ; Decision Support Systems, Clinical ; Drug Interactions ; Humans ; Medical Records Systems, Computerized ; Medication Errors/prevention & control ; Netherlands ; Prescriptions ; Risk Assessment/methods
    Sprache Englisch
    Erscheinungsdatum 2005-11-30
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article
    ZDB-ID 1018059-x
    ISSN 1179-1942 ; 0114-5916
    ISSN (online) 1179-1942
    ISSN 0114-5916
    DOI 10.2165/00002018-200528120-00007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2127: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang